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Abstract Depression is one of the widespread diseases
whose etiology is still unclear. Dysregulation of the hy-
pothalamic–pituitary–adrenal axis can be the cause of this
illness which is concomitant with a high level of cortisol.
For this reason, the purpose of the study was to estimate
the influence of the selective serotonin reuptake inhibitors
(SSRIs) therapy used in monotherapy and polypragmasy
on cortisol level in saliva of depressed women. Cortisol
was determined in saliva collected from 40 depressed
patients treated with SSRIs. HPLC with UV detection
was used for quantification of cortisol after its extraction
with dichloromethane. For statistical evaluation of the
data, the cluster analysis and principal components anal-
ysis were used. Results of the study have shown that the
SSRIs treatment reduces the cortisol level in saliva. The
therapy with sertraline and polypragmasy had a strong
influence on suppressing the cortisol secretion. Besides,
the amplitude of changes of the cortisol level during the
treatment had an impact on the duration of hospitaliza-
tion. In conclusion, it can be stet that the process of
reduction of the cortisol level is multiphasic and that
the combination treatment had a stronger influence on
suppressing the cortisol secretion than did antidepressants
used in monotherapy.
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Introduction
Cortisol is one of the most important steroid hormones
produced by the adrenal cortex, which controls the majority
of body metabolism. An increase in its level is concomitant
in many diseases, such as depression, which according to
WHO (2012), ranks fourth among common diseases in the
world. It is suggested that depression appears predominantly
in women population, and it can be caused by hormonal
changes in females’ organisms. Relation between depres-
sion and hormonal changes is evident during pregnancy and
postpartum. It is shown that postpartum period is the time of
greatest risk for development of major depressive disorder
(MDD), and more than 15 % young mothers are susceptible
to depression (Brummelte and Galea 2010).
The pathophysiology of the depression is unknown, but
there are some theories about it. The oldest one is based on
the role played by catecholamines, especially noradrenaline
and serotonin. The etiology of this theory is closely related
to first drugs, imipramine and iproniazid, used in the treat-
ment of depression. Nowadays, there are few groups of
antidepressant drugs. They can be classified based on their
influence on neurotransmitters. The most popular group of
antidepressants encompasses selective serotonin reuptake
inhibitors (SSRIs) which proved effective in the treatment
of MDD and also of obsessive compulsive disorder as well
as some other anxiety disorders (Humble 2000).
Several studies have revealed a close relation between
MDD and dysregulation of the hypothalamic–pituitary–adre-
nal (HPA) axis, such as a high cortisol level, non-suppression
of cortisol release by dexamethasone, or abnormal 24-
h cortisol secretion reported in patients with MDD (Plotsky
et al. 1998; Schüle 2006). On the other hand, the HPA axis
dysfunction can also be manifested as a mild hypocortisolism
during chronic fatigue syndrome (CFS). In both cases, MDD
and CFS, treatment with psychotropic medications can correct
HPA axis dysfunction (Papadopoulos et al. 2009, 2011).
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The administration of antidepressants which potentiate the
serotonin (5HT) and noradrenaline reuptake potentiates secre-
tion of the cortisol in healthy subjects as well. This stimulation
of the HPA activity can be caused by administration of SSRIs,
especially of citalopram and escitalopram. The endocrine
responses to administration of these drugs are probably due
to modulation of the serotonergic system and the HPA axis by
way of their effect on the sensitivity of either the 5HT1A
autoreceptor or the 5HT2 receptor (Attenburrow et al. 2001;
Harmer et al. 2003; Mondelli et al. 2006).
The desensitization of the presynaptic 5HT1A receptor by
citalopram and escitalopram is one of the hypotheses of the
antidepressant action (Sargent et al. 1998; Navinés et al. 2007;
Papakostas et al. 2010). Moreover, some studies have also
shown that antidepressant treatment might normalize activity
function of the HPA axis by increasing the expression of gluco-
corticoid receptors and in this way enhancing HPA feedback
mechanism (Pariante and Miller 2001; Okugawa et al. 1999).
In the majority of papers, the effects of antidepressant drugs
on the cortisol secretion have been studied mainly by moni-
toring its level at the beginning and the end of the therapy
(Harmer et al. 2003; Navinés et al. 2007; Papakostas et al.
2010; Aihara et al. 2007), but only in few papers there is
information that the cortisol level was repeatedly determined
during the therapy (Mück-Šeler et al. 2002; Rota et al. 2005).
The literature data have also shown that the treatment of
depression with SSRIs, such as citalopram (Mondelli et al.
2006; Nikisch et al. 2005), paroxetine (Mück-Šeler et al.
2002), and fluvoxamine (Aihara et al. 2007), mostly resulted
in the reduction of cortisol secretion. On the other hand, in
some studies changes in cortisol levels following the admin-
istration of SSRIs, such as sertraline, but also citalopram,
escitalopram, and paroxetine, have not been noticed at all
(Papakostas et al. 2010; Tucker et al. 2004a, b).
In summary, there is a paucity of unequivocal information
about the influence of the treatment of depression with SSRIs
on cortisol secretion. The purpose of the present study was to
learn whether or not the response to the treatment of depres-
sion is reflected by changes in saliva cortisol level during the
SSRIs therapy. The purpose was realised by the day-by-day
determination of the cortisol level in saliva of the depressed
women and by using pattern recognition methods, cluster
analysis (CA) and principal components analysis (PCA), for




Subjects with MDD defined according to the International
Classification of Diseases (ICD-10) (http://apps.who.int/
classifications/apps/icd/icd10online/) criteria were recruited
at the Hospital for Nervous and Mental Diseases in
Starogard Gdanski (Poland). The diagnoses were made by
a psychiatrist using the clinical interview. All the subjects
were informed in detail about the purpose of the study and
gave their written consent to participate in it, and they were
informed that they could discontinue the course at any time,
if desired.
Some of the subjects were excluded if they were unable
to understand the nature of the study after discussion with
research nurse, if their medical condition precluded admin-
istration of SSRIs or if they had serious health problems,
such as adrenal function disorders. Some other subjects
were also excluded because of pregnancy and breastfeeding
and if their participation in the course could be detrimental
to their well-being.
Finally, 40 patients aged 26–69 with MDD satisfying
inclusion criteria were entered into the study and enrolled
in medication treatment. Table 1 summarizes the demo-
graphic and clinical characterization of the subjects and a
detailed information on the antidepressants used and the
doses of drugs. The study had been approved by the ethical
committee of the Medical University of Gdansk, Poland.
Hormone assay
The salivary samples for determination of cortisol levels were
collected from depressed women every day during the whole
hospitalization period, including the first day. The samples
were collected into plastic tubes without any stimulation at
10 a.m. and frozen. The subjects were instructed to rinse their
mouths with water and not to eat or drink 30 min before the
samples were collected. A control group for evaluation of the
cortisol concentration consisted of ten healthy women. They
were recruited from students, who were free from psychotro-
pic medication. The mean age of volunteers was 23.1 (±1.7),
the mean weight was 54.3 kg (±6.0), and the mean BMI was
21.5 (±1.8). The sampling was carried out according to the
same procedure as that for the depressed subjects.
A new procedure has been elaborated for the determina-
tion of the cortisol level in saliva (Dziurkowska and
Wesolowski 2009). HPLC with UV detection at 240 nm
was used to quantify cortisol. The saliva samples obtained
from the depressed patients were refined by extraction with
dichloromethane. An acetonitrile/water (30:70 v/v) mixture
as a mobile phase and a chromatographic column with
reverse-phase C18 packing material as a stationary phase
were used. Carbamazepine was used as an internal standard
for calibration. The calibration curve was constructed by
plotting the ratio of peak height of cortisol to peak height
of internal standard vs. the cortisol concentration in saliva.
The stability of cortisol was checked by three freezing
and thawing cycles. The efficiency of extraction for two















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Salivary cortisol in women with major depressive disorder 141
concentrations (15 and 125 ng/mL) was checked, and the
recovery exceeded 94 % in both cases. Validation of the
method has shown that the coefficient of variation for the
intra-assay study varied from 1.1 to 6.5 %, and for the inter-
assay study, it did not exceed 6.8 %. The recovery fell in the
range 93.6 to 100.8 %.
Statistical methods
Two chemometric techniques, CA and PCA, were used for
data analysis (Hill and Lewicki 2006; Otto 1999). PCA
involved a mathematical procedure that transformed the
number of possibly correlated variables into a smaller num-
ber of orthogonal variables, called the principal components
(PCs), with the minimum loss of original information. A
two-dimensional score plot of PC1 vs. PC2 enabled classi-
fication of the studied subjects. On the other hand, CA
measured similarities or dissimilarities between the subjects
and classified these into groups. The distances between
groups of the subjects were calculated using Ward’s method
and the Euclidean distance.
In both cases (CA and PCA), the same matrix with 22
variables (age, hospitalization period and its multiplicity,
initial and final cortisol levels, the highest and lowest corti-
sol levels and difference between them, medium concentra-
tion, median of concentration, stabilization of cortisol
secretion at 8, 10, 15 ng/mL during the whole hospitaliza-
tion period and at different hospitalization phases) charac-
terizing all the studied subjects was used. Calculations were
accomplished using the Statistica 7.1 package (StatSoft,
Cracow, Poland).
Results
The results of the study are compiled in Table 1 and pre-
sented graphically in Fig. 1. As seen, 40 patients with mean
age of 49.3±9.7 were enrolled in the study. As many as 28
patients received SSRIs in the monotherapy (MT) and 12 in
the combination therapy (CT). All subjects completed the
study with a mean duration of hospitalization of 41.3±
21.1 days and the mean multiplicity of 2.8±2.1. Mean initial
and final cortisol levels in saliva were 45.76±36.37 and
18.30±39.99 ng/mL, respectively.
Based on the performed studies, it can be stated that in
the case of:
1. Patient’s organism responded to treatment, the cortisol
level dropped very quickly to attain the reference value
of 1–8 ng/mL and did not increase up to the end of
hospitalization (Fig. 1a). The difference between corti-
sol levels as determined day-by-day did not exceed few
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SSRIs had just that shape of the profile of cortisol
secretion. It was independent of the course of the anti-
depressant therapy;
2. Patients treated with SSRIs in the MT course, who
stayed at the hospital for more than 30 days, an increase
in the secretion of cortisol on about 30th day of the
therapy was noticed. After the next few days, the level
of the hormone declined (Fig. 1b). In the majority of
subjects, the cortisol level on those days was lower than
the initial one. This shape of the profile of cortisol
secretion was recorded in nine patients. In these cases,
the amplitude of the cortisol level, as determined day-
by-day, was large, especially at the beginning of the
hospitalization. Moreover, the difference between the
cortisol levels determined day-by-day fell in the range
of several or several dozen nanograms per milliliter;
3. Patients with a large fluctuation of the cortisol level, the
hospitalization period of those patients was longer, and
they had already been repeatedly hospitalized because
of the depression (Fig. 1c). The patients treated with
citalopram and escitalopram represented this group in
particular. When the CT-treated patients were excluded,
in spite of prolonged hospitalization, the amplitude of
cortisol level did not exceed 10 ng/mL;
4. Patients who underwent combined treatment and their
hospitalization period was longer than 30 days, the sec-
ondary rise in the cortisol level was missing (Fig. 1d);
5. The therapy with fluvoxamine, the cortisol level attained
stabilization at a characteristic for the patient level in
response to the treatment;
6. Almost all of the patients, the final cortisol level was
lower than that at the beginning of the therapy.
To verify these results, they were examined using cluster
analysis and principal component analysis. A CA dendro-
gram presented in Fig. 2a shows that 22 variables charac-
terizing the patients were grouped into three clusters at a
level of 1/3 of the maximum distance. In this way, the results
of CA calculation allowed to find a strong correlation be-
tween stabilization of the cortisol secretion at different
Fig. 1 Changes of cortisol concentration in saliva of patients treated with:
a sertraline (patient no. 39), b escitalopram (patient no. 25), c citalopram
(patient no. 30), d CT, sertraline with trazodone (patient no. 10)
Fig. 2 Dendrograms illustrating clustering of 22 variables (a) and 40
patients (b), based on the data on Table 1
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levels during the whole hospitalization period and at differ-
ent phases of the treatment, and also between the hospital-
ization period and the age of the patient. These variables
formed cluster I. The strong correlations among the multi-
plicity of hospitalization, the lowest, medium, and final
cortisol levels, and median of concentration were found.
These variables formed cluster II. Furthermore, cluster III
was formed by three other variables: initial cortisol level at
the beginning of hospitalization, the highest level during the
hospitalization, and the difference between the highest and
the lowest cortisol levels. These variables are grouped with
those contained in cluster II at a level of 1/2 of the maximum
distance.
As shown in Fig. 2b, all the patients were grouped into
separate clusters based on variations of the amplitude of the
cortisol level in saliva. At a level of 1/3 of the maximum
distance there are four clusters. The first cluster (Ia) encom-
passes patients with a small amplitude in the hormone level, a
few nanograms per milliliter, matching that of the references
values. The majority of these subjects were hospitalized for
the first time. This cluster represents patients with cortisol
changes profiles shown in Fig. 1a, d. The opposite group IV
is formed by subjects with very high initial or final concen-
trations of cortisol, above 140 ng/mL. In an exceptional case,
the level of the cortisol secretion was very high, and there was
no stabilization of the hormone secretion during the whole
time of hospitalization. This cluster encompassed patients
with a cortisol changes profile represented in Fig. 2b.
Clusters Ib–III are formed by those subjects who had
some periods of suppression of the cortisol secretion during
the hospitalization, and they were clustered in accordance
with a period of time over which the depressed secretion of
the cortisol has been noticed. Cluster Ib grouped patients
with an enhanced fluctuation of cortisol secretion, in partic-
ular at the beginning of therapy. Cluster II was formed by
patients with a very short time of stabilization of the cortisol
secretion. This group encompasses the subjects whose se-
cretion of the cortisol was higher than in the healthy ones,
but attained stabilization at the characteristic level in re-
sponse to the treatment. Almost all of the subjects were
hospitalized because of the depression more than twice. As
shown in Fig. 1c, patients with a large amplitude of cortisol
level, especially at the beginning of therapy and at its end,
formed cluster III. The mean hospitalization period in this
group was 53.9 days.
The results of PCA calculations are presented in Fig. 3a,
b as two-dimensional plots of PC1 vs. PC2. The first two
principal components occupied together 66.5 % of the var-
iance. This multivariate approach demonstrates that the var-
iable with the most significant impact on the classification
of the subjects according to the PC1 axis was the hospital-
ization period, at which the cortisol level was similar to the
reference value. The medium concentration and median of
concentration were important as well. According to the PC2
axis, the highest and the lowest cortisol levels and the
difference between them were the most important factors
for classification of the patients.
As shown in Fig. 3a, PCA confirms the results obtained
by CA. Group I was formed by patients with a slightly
elevated cortisol level and with small fluctuation or normal
secretion of the hormone. Patients who were repeatedly
hospitalized due to depression and had a fluctuating cortisol
level with a short period of stabilization of the cortisol
secretion fall in cluster II. Moreover, cluster III contains
patients with a large amplitude of cortisol secretion, espe-
cially at the beginning and at the end of the therapy, whereas
cluster IV is formed by the same patients as those grouped in
cluster IV in the CA dendrogram (Fig. 2b).
Fig. 3 PCA score plots for the first two principal components showing
the grouping of the patients mainly due to the hospitalization period (a)
and the therapy used (b). Antidepressants used in the therapy: black
diamond sertraline, white diamond CT, black square citalopram, white
square escitalopram, asterisk paroxetine, plus sign fluoxetine, black
triangle fluvoxamine
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PCA has also shown that patients can be grouped accord-
ing to the antidepressants used for the treatment of depres-
sion. As shown in Fig. 3b, patients treated with sertraline
and undergoing the combined treatment formed characteris-
tic concentrations. The subjects were characterized by a
smaller fluctuation of the cortisol level during the hospital-
ization than those with normal secretion of cortisol. These
patients fall in cluster I in Fig. 3a. These patients also
formed cluster I in the CA dendrogram, which contains 23
patients, 16 of them were treated with sertraline and CT. The
profiles of cortisol changes in these patients are shown in
Fig. 1a, d.
Discussion
An increase in cortisol secretion, as a result of dysregulation
of the HPA axis, can be one of the symptoms of depression.
The literature data have also shown that cortisol can be one
of the direct factors involved in the pathogenesis of depres-
sion (Plotsky et al. 1998; Schüle 2006). Following these
information, the influence of SSRIs used in the MT and CT
on cortisol secretion which is reflected by its concentration
in saliva collected from patients hospitalized because of the
depression was examined.
Cortisol is secreted in diurnal cycle. The highest level of
this hormone in the blood is observed at about 8 a.m. and falls
down during the day. Hence, the cortisol concentration is the
lowest in the evening. Taking into account that in a healthy
adult only 1 % of the cortisol is excreted with urine and saliva
(Chrousos 2011), the highest cortisol level in saliva occurs
between 9 and 10 a.m. For this reason, it was decided that the
sampling of the patients’ saliva will take place at 10 a.m.
To reduce the possibility that anxiety related to the blood
sampling might affect cortisol level, the saliva was chosen as
the diagnostic material. Moreover, in the case of depression,
apathy of the patients could remarkably influence collaboration
between patient and the research nurse. According to the
literature data, there is a strong correlation between the cortisol
level in the blood and in saliva (Baghai et al. 2002; Bhagwagar
et al. 2002; Lilliecreutz et al. 2011). In these diagnostic materi-
als, cortisol can be quantified by using either non-separation
methods, such as radioimmunoassay (Tucker et al. 2004a; Rota
et al. 2005) and enzyme immunoassay (Masharani et al. 2005)
or separation methods, such as liquid chromatography with
tandemmass spectrometry (Gröschl and Rauh 2006). The non-
separation methods are quite frequently used owing to their
rapidity; however, sometimes a liquid–liquid extraction before
the analysis is preferable. Furthermore, the limits of detection
and quantification are overall lower than those obtained for
separation methods. On the other hand, the separation methods
are more accurate due to lack of cross-reactions. The cross-
reactions are crucial for steroids quantitation, but they are
undesirable because the same antibody can react with steroid
hormones having similar structure, and in consequence, the
result of determination becomes overestimated. For these rea-
sons, the separation method based on HPLC with UV detec-
tion was used for cortisol quantitation in saliva (Dziurkowska
and Wesolowski 2009) because it prevented even a slight
overstatement of the analysis result.
A literature survey shows that in most cases, cortisol was
determined before and after the therapy. In the majority of
studies, the decreasing cortisol secretion was reported as an
effect of the SSRIs therapy (Mondelli et al. 2006; Aihara et
al. 2007; Rota et al. 2005; Nikisch et al. 2005), as has also
been found in this study. In most cases, the drop in cortisol
level occurred during the antidepressant treatment, indepen-
dently of the kind of the applied SSRI drug. In some cases,
the reference values of cortisol level (1–8 ng/mL) were not
attained, but the amplitude of the cortisol fluctuation deter-
mined day-by-day was smaller. This reflected a positive
reaction of the subject’s organism to the antidepressant
therapy and contributed to shortening of hospitalization.
The results of the investigation have shown that in the
case of patients who were hospitalized for more than
30 days, a secondary rise in the cortisol secretion occurred
on about the 30th day of the therapy. However, the cortisol
level found on those days was lower than the initial one and
after next few days it was declining. Moreover, in the case
of citalopram treatment, after the secondary increase in
cortisol secretion, the fluctuation of the hormone level be-
came larger. Patients treated with CT (SSRIs in polyprag-
masy with venlafaxine, trazodone, or mianserin) were the
exceptions. In spite of the prolonged hospitalization, the
secondary rise in the cortisol level was missing.
According to the literature data, the cortisol level was
determined only before and after the therapy, and its fluctu-
ation during the treatment was not monitored. Only a few
papers report that the cortisol level during the therapy was
also determined (Mück-Šeler et al. 2002; Rota et al. 2005).
This study has shown that the frequency of determination of
the cortisol concentration is crucial because even a several-
day interval in the assays can make that impact of the
therapy on the cortisol secretion and the amplitude of the
hormone level could not be noticed. The day-by-day deter-
mination of the level is important especially in the case of
the therapy with a drug which may modulate the activity of
5HT receptors, e.g., citalopram (Papakostas et al. 2010;
Tucker et al. 2004a, b). Otherwise, the actual changes of
the cortisol level during the therapy could not be found, as
has also been confirmed in the literature (Rota et al. 2005).
The performed study on the influence of SSRIs used in
the MT and CT on the cortisol secretion has also shown that
the antidepressant therapy with SSRIs reduces the symp-
toms of depression and suppresses cortisol secretion.
Furthermore, patients treated with CT achieved a quicker
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normalization of the cortisol secretion, as has also been
reported in other studies. However, CT has been found to
prevent the occurrence of an enhanced night salivary corti-
sol (Yang et al. 2009). Besides, the study confirmed that CT
has a significant influence on the cortisol secretion, as
shown by PCA and CA. The majority of patients treated
with CT were grouped in cluster I, which contains patients
whose cortisol secretion and the amplitude of the hormone
level decreased very quickly.
CA and PCA also demonstrated that sertraline used in the
MT and CT, and escitalopram and citalopram used in CT,
are the most effective drugs in the reduction of cortisol
secretion during the treatment. Moreover, it was found that
among patients good reacting to the therapy with antide-
pressants, independently of the mechanism of action of
these medicines, the recovery was quick. It was manifested
by a decrease in the cortisol concentration and a short period
of hospitalization, which did not exceed 20 days.
In conclusion, this study enabled monitoring of the
changes in cortisol level in saliva collected from hospital-
ized depressed patients treated with SSRIs in the MT and
CT. The cortisol level was determined every morning during
the whole period of hospitalization. Based on the results and
their interpretation with the aid of multivariate statistical
analysis, it can be stated that SSRIs therapy suppresses the
cortisol secretion, but the process is complex and multiphasic.
The amplitude of cortisol secretion determined day-by-day is
the most important factor that has an impact on hospitalization
period of depressed patients. The study has also demonstrated
that CT, in particular the polypragmasy with sertraline and
trazodone, has a stronger impact on suppressing the cortisol
secretion than do antidepressants used in MT.
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